Search Results
Your search for can matches 13754 pages
Showing 2701 - 2750Study Investigates Possible Link Between Risk of Breast Cancer in Males and Male Infertility
The risk of invasive breast cancer in men may be associated with self-reported infertility, according to a study published by Swerdlow et al in the journal Breast Cancer Research. The authors interviewed 1,998 males in England and Wales diagnosed with breast cancer, with 112 (5.6%) also...
CoVac-1 Vaccination Studied for Prevention of Severe COVID-19 in Immune-Deficient Patients With Cancer
CoVac-1, a multipeptide COVID-19 vaccine candidate, elicited immunogenicity in patients with cancer and disease-related or treatment-related immunoglobulin deficiency in a phase I/II trial reported at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 These patients are...
Colonoscopy After Positive FIT Test May Reduce Risk of Death From Colorectal Cancer
Recent research underlines the importance of following up with a colonoscopy exam after a positive result on an at-home stool test to screen for colorectal cancer. The test, known as the fecal immunochemical test (FIT), checks for traces of blood in patient-collected stool samples, which can be an...
Report Finds Uptake of Erdafitinib for Urothelial Cancer May Be Limited, Despite Positive Real-World Survival Data
The first bladder cancer drug targeting a cancer-driving gene mutation has been used relatively little despite its clear efficacy in a clinical trial, suggests a report published as a research letter by Nimgaonkar et al in JAMA Oncology. Researchers analyzed a large, nationwide database of cancer...
Next-Generation PARP1-Selective Inhibitor Offers Significant Benefits Over Older Predecessors in Treatment of Solid Tumors
The first-in-human, first-in-class trial of the next-generation PARP (poly [ADP-ribose] polymerase) 1–selective inhibitor AZD5305 suggests this drug may be a welcome advance over its U.S. Food and Drug Administration (FDA)-approved predecessors in the treatment of solid tumors with alterations in...
Report Investigates Potential Causes of Decreasing Responses to CAR T-Cell Therapy in Patients With Non-Hodgkin Lymphoma
A study published by Jackson et al in Cancer Discovery investigated the reasons for decreased remission rates for patients with non-Hodgkin lymphoma treated with chimeric antigen receptor (CAR) T-cell therapy. "CAR T-cell therapy is a promising treatment for non-Hodgkin lymphoma, especially for...
Polygenic Score May Enable More Precise PSA Screening for Prostate Cancer
The use of a polygenic score incorporating variations in prostate-specific antigen (PSA) values that are not due to cancer may allow for more precise PSA screening, according to findings of a large genome-wide association study presented at the American Association for Cancer Research (AACR) Annual ...
New Research Encourages Harnessing Health Technology to Help Patients With Cancer Quit Smoking
New research published by Ramsey et al in JNCCN—Journal of the National Comprehensive Cancer Network has found that the inclusion of the smoking cessation tool Electronic Health Record–Enabled Evidence-Based Smoking Cessation Treatment (ELEVATE) into electronic health records may increase...
Report Finds Targeting IL-6 May Help to Relieve Immunotherapy Side Effects
Researchers at The University of Texas MD Anderson Cancer Center have identified a novel strategy to reduce immune-related adverse events caused by immunotherapy by targeting the cytokine interleukin-6 (IL-6). The study, published by Hailemichael et al in Cancer Cell, establishes a proof of concept ...
Beyond Immunotherapy: New Targeted Agents for Advanced NSCLC
The advent of PD-1 and PD-L1 checkpoint inhibitors has changed the treatment landscape of advanced non–small cell lung cancer (NSCLC), but only approximately 20% of patients treated with immunotherapy will be alive at 5 years. According to Melissa L. Johnson, MD, Director, Lung Cancer Research,...
ASTRO Issues Clinical Guideline on Radiation Therapy for Brain Metastases
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance on the use of radiation therapy to treat patients with brain metastases. Evidence-based recommendations guide the multidisciplinary planning and delivery of advanced radiation therapy techniques to...
Short and Shorter Screening Tools for Food Insecurity
A survey of oncology registered dietitian nutritionists (RDNs)1 found that most of those surveyed were not using a validated assessment tool to identify food insecurity but expressed interest in obtaining the Six-Item Short Form of the Food Security Survey Module.2 The six-item food insecurity...
Assessing Food Insecurity Among Patients With Cancer
Food insecurity, particularly as it affects cancer survivors, is a serious problem, according to a survey of oncology registered dietitian nutritionists (RDNs) published in the Journal of the Academy of Nutrition and Dietetics.1 “Despite these concerns, most oncology RDNs interviewed are not using...
Music Interventions for Improving Psychological and Physical Symptoms in People With Cancer
Guest Editor’s Note: Cancer and its treatments are associated with both physical and psychological symptoms that can have substantial impact on patients’ quality of life. Music therapy is a complementary modality that is being increasingly used for cancer symptom management. In this article, Joke...
The WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Drs. Syed Ali Abutalib and L. Jeffrey Medeiros explore the updated World Health Organization (WHO) classification of hematopoietic and lymphoid tissue...
From a Small Village in China to Cutting-Edge Clinical Cancer Research for Cynthia X. Ma, MD, PhD
Cynthia X. Ma, MD, PhD, was born in a small village in Hebei, a province in the Central China region. “I grew up in a poor village with less than 1,000 people. We had no medical services in our village, so we had to travel to the city to see a doctor, which was quite some distance away. In the...
DESTINY-Lung01: Is Trastuzumab Deruxtecan the Answer for HER2-Mutant Lung Cancer?
The human epidermal growth factor (HER) family of receptors are a well-established therapeutic target. Indeed, seminal studies conducted nearly 2 decades ago identified a key association between activating mutations in the kinase domain of the epidermal growth factor receptor (EGFR, also known as...
ASCO Honors 2022 Special Awards Recipients
ASCO and Conquer Cancer, the ASCO Foundation, will recognize researchers, patient advocates, philanthropists, teachers, and global oncology leaders who have reshaped cancer care around the world with the Society’s highest honors at the 2022 ASCO Annual Meeting in Chicago. Hear from select award...
J. Paul Taylor, MD, PhD, Named Scientific Director and Executive Vice President of St. Jude
J. Paul Taylor, MD, PhD, has been named Scientific Director and Executive Vice President of St. Jude Children’s Research Hospital. Dr. Taylor steps into the role during a pivotal time of growth for the hospital. Under its $11.5 billion, 6-year strategic plan, the institution’s scientific...
Absence of FAM19A4/miR124-2 DNA Methylation and Clinical Regression of High-Grade Cervical Intraepithelial Neoplasia
In the Dutch CONCERVE study reported in the Journal of Clinical Oncology, Kremer et al found that the absence of FAM19A4/miR124-2 DNA methylation was associated with a high rate of clinical regression of high-grade cervical intraepithelial neoplasia over 24 months among women treated with a...
Natural Killer Cells Precomplexed With Innate Cell Engager Show Activity in CD30-Positive Lymphoma
Natural killer (NK) cells derived from donated umbilical cord blood, activated with a novel bispecific antibody targeting CD16A and CD30 known as AFM13, have yielded responses in patients with pretreated and refractory CD30-positive lymphoma. The overall response rate was 89%, with 53% complete...
Going the Last Mile: Accelerating Delivery of Multiple Myeloma Therapies to All Patients
When I was diagnosed with multiple myeloma in 1996, I was given 3 years to live. At the time, there was little understanding of this disease, which was termed incurable. There were no new treatments, few drugs in the pipeline, hardly any clinical trials, and no multiple myeloma community or...
Expert Point of View: Mark Awad, MD, PhD
“In the past decade, major improvements in treating lung cancer have come from identification of mutations and development of drugs to target those mutations: EGFR, ALK, RET, HER2, and others. Finally, we can add KRAS as a druggable target,” stated invited discussant Mark Awad, MD, PhD, Clinical...
Hematologic Oncology 2021–2022 Almanac
Ongoing evaluation of novel, targeted, and immunotherapies has led to exciting advances across the array of hematologic malignancies over the past year. The availability of new treatment options, along with emerging data on novel combinations and sequencing approaches, is rapidly changing...
BELINDA Trial: CAR T-Cell Therapy Fails to Improve Outcomes in Aggressive Non-Hodgkin Lymphoma
The autologous chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel failed to improve event-free survival vs standard-of-care treatment strategies in patients with aggressive, relapsed or refractory non-Hodgkin lymphoma (NHL), according to results of the phase III BELINDA trial,...
Expert Point of View: Jane N. Winter, MD and Christopher R. Flowers, MD, MS
Jane N. Winter, MD, Professor of Medicine at Northwestern University’s Feinberg School of Medicine and the 2022 President of the American Society of Hematology (ASH), and Christopher R. Flowers, MD, MS, Chair of the Department of Lymphoma/Myeloma at The University of Texas MD Anderson Cancer...
POLARIX: Addition of Polatuzumab Vedotin-piiq to Standard of Care Significantly Reduces Progression of Diffuse Large B-Cell Lymphoma
As a first-line treatment of inter-mediate- or high-risk diffuse large B-cell lymphoma, the addition of the antibody-drug conjugate polatuzumab vedotin-piiq to standard-of-care therapy resulted in a 27% reduction in the relative risk of disease progression, relapse, or death, with a similar safety...
ZUMA-7: Axicabtagene Ciloleucel Quadruples Event-Free Survival in Large B-Cell Lymphoma
In the primary analysis of the phase III ZUMA-7 trial, examining second-line therapy for relapsed or refractory large B-cell lymphoma, the CAR T-cell therapy axicabtagene ciloleucel led to a fourfold increase in event-free survival over the standard of care. These findings were presented at the...
Expert Point of View: Susan M. O’Brien, MD
The GAIA trial raises some important points, according to Susan M. O’Brien, MD, Associate Director for Clinical Research at the UCI Chao Family Comprehensive Cancer Center in Irvine, California. Dr. O’Brien co-moderated the session where Dr. Eichhorst presented study results. “The CLL14 trial...
Expert Point of View: Joshua Brody, MD
Joshua Brody, MD, Director of the CLL/Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, New York, who was not involved in these trials, commented: “CLL is an extremely prevalent disease affecting nearly 200,000 patients in the United States. Most patient do not require...
Fixed-Duration Venetoclax Plus Ibrutinib Achieves Deep and Durable MRD Remissions in CLL
Two different trials presented at the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition found that fixed-duration treatment with ibrutinib and venetoclax achieved deep and sustained undetectable measurable residual disease (MRD) status when used as first-line therapy for...
Zanubrutinib Superior to Ibrutinib for CLL/SLL in Phase III ALPINE Trial
Zanubrutinib, a second-generation Bruton’s tyrosine kinase (BTK) inhibitor, significantly improved response rates and delayed disease progression as compared with the standard of care, ibrutinib, in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma...
Can AI Assist in Predicting Spinal Fractures in Patients With Cancer?
A new study published by Ahmadian et al in the International Journal for Numerical Methods in Biomedical Engineering suggests how scientists may use artificial intelligence (AI) to predict how cancer may affect the probability of fractures along the spinal column. The report described how the...
Study Examines Link Between Emphysema and Lung Cancer Risk
Computed tomography (CT)-detected emphysema may be linked to a higher risk of lung cancer, a risk that increases with emphysema severity, according to a new study published by Yang et al in the journal Radiology. Lung cancer is the primary cause of cancer-related death worldwide. However, lung...
Topical Imiquimod vs Surgery for Vulvar High-Grade Squamous Intraepithelial Neoplasia
In an Austrian phase III trial reported in The Lancet, Trutnovsky et al found that topical imiquimod was noninferior to surgery as measured by complete clinical response in patients with vulvar high-grade squamous intraepithelial lesions. Study Details In the multicenter trial, 107 evaluable...
Study Reports New Potential Target for CAR T-Cell Therapy
Chimeric antigen receptor (CAR) T-cell therapy has made an impact on the treatment of certain blood cancers, but in clinical study, the cellular therapy has not been as successful for patients with solid tumors, due in part to the lack of tumor targets not expressed in vital tissues. In a new study ...
Demystifying Immunotherapy for Early-Stage Triple-Negative Breast Cancer
Immunotherapy has become a potential strategy in treating triple-negative breast cancer, though many questions remain to be answered before long-term survival is achieved by all patients. This exciting field of breast cancer research was explored at the 2022 Miami Breast Cancer Conference by...
ASCO’s CancerLinQ® and Atropos Health Collaborate to Harness Real-World Data to Provide Point-of-Care Informatics Consult to Oncologists
ASCO’s CancerLinQ® and Atropos Health announced today a new collaboration that will provide oncology clinicians with the latest real-world evidence available to help inform personalized care and treatment of an individual patient.Atropos Health and CancerLinQ will work together to provide a...
Case Study Examines Differences Between AI and Radiologist Perception in Breast Cancer Screening
Radiologists and artificial intelligence (AI) systems yield significant differences in breast cancer screenings, a team of researchers has found. The case study by Makino et al, which appears in the journal Nature Scientific Reports, reveals the potential value of using both human and AI methods in ...
Study Identifies Genetic Changes in Patients With Barrett’s Esophagus That Progresses to Esophageal Cancer
Using whole-genome sequencing to contrast genomic alterations in patients with stable Barrett’s esophagus compared to patients whose Barrett’s progressed to esophageal adenocarcinoma, Paulson et al reported that DNA changes presaging esophageal cancer can be spotted years before cancer develops....
Gut Microbiome May Alter Response to Cancer Therapy
Recent findings with the use of sequencing technology have suggested that the gut microbiome may play a role in the treatment of cancer. A review paper published in JAMA Oncology by Liu and Shah captured the current understanding of the connection between the gut microbiome and therapeutic response ...
How to Get the Dose Right
OCE Insights is an occasional column developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the U.S. Food and Drug Administration (FDA). In this installment, Mirat Shah, MD, of the Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA; Atiqur...
Study Finds CAR T-Cell Therapy Outcomes, Side Effects Are Similar in Black and Hispanic Patients Compared to White and Asian Patients
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of blood cancers, including certain leukemias, lymphomas, and multiple myeloma. However, Black and Hispanic patients were largely absent from the major clinical trials that led to the U.S. Food and Drug Administration...
Preoperative Radiotherapy and DIEP Flap Reconstruction in Women Requiring Mastectomy for Breast Cancer
In the PRADA study—reported by Thiruchelvam et al in The Lancet Oncology—researchers found that a strategy of preoperative radiotherapy and deep inferior epigastric perforator (DIEP) flap reconstruction was feasible and safe in women requiring mastectomy for breast cancer. As stated by the...
Updated Guidance for COVID-19 Vaccination From NCCN Recommends Fifth mRNA Shot (Second Booster Dose) for Immunocompromised People
The National Comprehensive Cancer Network® (NCCN®) has released the latest recommendations from the NCCN Advisory Committee on COVID-19 Vaccination and Pre-exposure Prophylaxis. The updated recommendations point to two booster vaccine doses for people who are immunocompromised (meaning three...
Timothy A. Yap, MBBS, PhD, on Developing Novel Therapeutic Strategies to Target DNA Damage Response in the Clinic
Timothy A. Yap, MBBS, PhD, of The University of Texas MD Anderson Cancer Center, discusses how research is building on the success of first-generation PARP inhibitors in the clinic and the potential of novel potent PARP1-selective inhibitors, which may lead to improved patient outcomes. Given...
Some Recurrences of Ductal Carcinoma In Situ May Be Genetically Distinct From the Primary Tumor, Study Reports
Contrary to what has been assumed, all recurrences of ductal carcinoma in situ (DCIS) are not genetically the same, according to a study presented at the American Association for Cancer Research (AACR) Annual Meeting 2022.1 Almost 20% of ipsilateral recurrences found in the study were genetically...
Two Studies Examine Use of Proton-Beam Therapy in the United States
Two new, large studies led by researchers at the American Cancer Society showed an increase in the use of proton-beam therapy for patients with cancer in the United States during the past decade. However, Black patients were less likely to receive proton-beam therapy than White patients, and the...
Study Examines Rates of Psychiatric Disorders and Self-Harm Among Patients Diagnosed Across 26 Cancer Types
The risk of self-harm after incident psychiatric disorder diagnosis in patients with 26 cancer types and the risk of unnatural deaths after self-harm were examined in 459,542 individuals in a study published by Chang et al in Nature Medicine. Patients with cancer may experience substantial...
AI May Assist Physicians in Better Assessing the Effectiveness of Bladder Cancer Treatment
In a small multi-institutional study, an artificial intelligence (AI)-based system improved providers’ assessments of whether patients with bladder cancer had complete response to chemotherapy before a radical cystectomy. These findings were published by Sun et al in Tomography. Yet the researchers ...
